Seattle Genetics clears FDA hurdle for potentially most lucrative application of cancer drug Adcetris

Approval of Adcetris as a first line of treatment for patients with advanced lymphoma could push sales past $1 billion in the U.S.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news